Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
RenovoRx Inc (RNXT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: RNXT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -46.33% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 35.53M USD | Price to earnings Ratio - | 1Y Target Price 4.88 |
Price to earnings Ratio - | 1Y Target Price 4.88 | ||
Volume (30-day avg) 88803 | Beta 1.15 | 52 Weeks Range 0.77 - 1.69 | Updated Date 04/1/2025 |
52 Weeks Range 0.77 - 1.69 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.57 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -93.31% | Return on Equity (TTM) -258.95% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 25682164 | Price to Sales(TTM) - |
Enterprise Value 25682164 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -4.72 | Shares Outstanding 35565300 | Shares Floating 23693162 |
Shares Outstanding 35565300 | Shares Floating 23693162 | ||
Percent Insiders 1.29 | Percent Institutions 2.85 |
Analyst Ratings
Rating 4.67 | Target Price 5.5 | Buy 1 | Strong Buy 2 |
Buy 1 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
RenovoRx Inc
Company Overview
History and Background
RenovoRx Inc. is a biopharmaceutical company founded in 2009 focused on developing targeted therapies for cancer. It aims to improve cancer treatment outcomes using its proprietary RenovoCath delivery system.
Core Business Areas
- Trans-Arterial Micro-Perfusion (TAMP) Therapy: RenovoRx develops and commercializes TAMP therapy using its RenovoCath delivery system, designed to deliver therapeutic agents directly to tumors via arterial blood vessels.
- RenovoCath Delivery System: The RenovoCath is a proprietary micro-infusion catheter designed to deliver therapeutic agents directly to selected sites in the body, including tumors, via local perfusion.
Leadership and Structure
Shaun Bagai is the CEO. The company has a standard organizational structure with departments for clinical development, manufacturing, regulatory affairs, and commercial operations.
Top Products and Market Share
Key Offerings
- RenovoCath: RenovoCath is the company's primary product, a micro-infusion catheter used for targeted drug delivery. Market share data is unavailable due to the early stage and niche application. Competitors include companies offering similar catheter-based drug delivery systems, such as Boston Scientific and Medtronic, but none that focus solely on local perfusion for cancer. Revenue for 2023: $143,000
Market Dynamics
Industry Overview
The industry encompasses targeted drug delivery systems for cancer treatment. It's a growing market driven by the need for more effective and less toxic cancer therapies.
Positioning
RenovoRx is positioned as a company focused on innovative, targeted drug delivery for solid tumors, offering a unique local perfusion approach. Its competitive advantage lies in its proprietary RenovoCath delivery system.
Total Addressable Market (TAM)
The TAM for targeted cancer therapies is estimated to be in the billions of dollars. RenovoRx is focusing initially on specific cancers where local perfusion can offer a significant benefit, and will expand over time.
Upturn SWOT Analysis
Strengths
- Proprietary RenovoCath delivery system
- Targeted drug delivery approach
- Potential for improved treatment outcomes
- Focus on underserved cancer types
Weaknesses
- Limited commercialization experience
- Reliance on a single product
- High cash burn rate
- Need for additional clinical trial data
Opportunities
- Expansion into new cancer indications
- Partnerships with pharmaceutical companies
- Increased adoption of targeted therapies
- Positive clinical trial results
Threats
- Competition from established medical device companies
- Regulatory hurdles
- Failure to achieve clinical trial endpoints
- Market acceptance of RenovoCath
Competitors and Market Share
Key Competitors
- BSX
- MDT
- Varian (Siemens Healthineers)
Competitive Landscape
RenovoRx is a small player in a market dominated by large medical device companies. Its competitive advantage lies in its specialized delivery system, while its disadvantage is its limited resources.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: RenovoRx's growth is primarily driven by clinical trial progress and regulatory milestones. Revenue growth has been limited as they await approvals.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization efforts. Analyst estimates are speculative at this stage.
Recent Initiatives: Focus on the Phase III trial of RenovoCath in pancreatic cancer, exploring additional indications, and pursuing strategic partnerships.
Summary
RenovoRx is a high-risk, high-reward biopharmaceutical company with a focus on targeted cancer therapies. Its proprietary delivery system holds promise, but the company faces challenges in clinical development, regulatory approval, and commercialization. Success hinges on positive clinical trial results and strategic partnerships. Investors should be aware of the significant financial risks associated with early-stage companies in the biotech sector.
Similar Companies
- BSX
- MDT
- VAR
Sources and Disclaimers
Data Sources:
- RenovoRx Inc. SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Please consult with a qualified financial advisor before making any investment decisions. Market share estimates are based on available data and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About RenovoRx Inc
Exchange NASDAQ | Headquaters Los Altos, CA, United States | ||
IPO Launch date 2021-08-26 | CEO, Secretary & Director Mr. Shaun R. Bagai | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://renovorx.com |
Full time employees 8 | Website https://renovorx.com | ||
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.